Skip to main content

Table 1 Selected clinical characteristics according to hospital discharge or death and multivariate logistic regression analysis with and without inverse weight propensity score adjustment with death as outcome

From: Impact of androgen deprivation therapy on mortality of prostate cancer patients with COVID-19: a propensity score-based analysis

Characteristic

Alive

(n = 67)

Death

(n = 132)

All patients

(n = 199)

Pa

OR UNI (95% CI)

Pb

OR MV (95% CI)

Pb

OR IWDRE

(95% CI)

Pb

Age

≤ 75 years

40 (59.7)

64 (48.5)

104

       

> 75 years

27 (40.3)

68 (51.5)

95

0.176

1.57 (0.87–2.86)

0.136

1.63 (0.89–2.99)

0.115

1.03 (0.56–1.91)

0.924

Comorbidities

Heart disease

25 (37.3)

56 (42.4)

81

0.543

1.24 (0.68–2.26)

0.488

    

Diabetes

16 (23.9)

33 (25.0)

49

1.000

1.06 (0.54–2.11)

0.863

    

Neurologic disease

2 (3.0)

9 (6.8)

11

0.340

2.38 (0.5–11.33)

0.277

    

Asthma

2 (3.0)

4 (3.0)

6

1.000

1.02 (0.18–5.69)

0.986

    

Chronic lung disease

5 (7.5)

12 (9.1)

17

0.794

1.24 (0.42–3.68)

0.698

    

Nephropathy

4 (6.0)

17 (12.9)

21

0.151

2.33 (0.75–7.22)

0.143

2.06 (0.65–6.57)

0.22

2.2 (0.65–7.36)

0.203

Critical presentation

3 (4.5)

60 (45.4)

63

 < 0.001

      

Southeast

45 (67.2)

76 (57.6)

121

0.220

0.66 (0.36–1.23)

0.192

0.64 (0.34–1.2)

0.166

0.3 (0.15–0.61)

0.001

Active ADT

56 (83.6)

100 (75.8)

156

0.274

0.61 (0.29–1.31)

0.208

0.63 (0.29–1.37)

0.241

0.7 (0.38–1.31)

0.263

Palliative treatment

61 (91.0)

118 (89.4)

179

0.807

0.83 (0.3–2.27)

0.715

    
  1. ADT, Androgen deprivation therapy; OR, odds ratio; UNI, Univariate; MV, Multivariate; IWDRE, Inverse weight double robust estimation
  2. aFisher exact test
  3. bWald test